OCC 1.25% 39.5¢ orthocell limited

Ann: OrthoATI Tendon Clinical Study Success, page-89

  1. 231 Posts.
    lightbulb Created with Sketch. 38
    I would not be overly concerned about the 11% rise on a great trial result As Bedger has mentioned before Aus retail /instos do not understand cutting edge biotech stock like this. There is no venture capital for this type of thing in aus. We need to be a meme stock
 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.